(Ad26.COV2.S)
This site is intended for US healthcare professionals to access current scientific information about Janssen products. It is prepared by Janssen Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 12/26/2022
For complete information, please review the Janssen COVID-19 Vaccine Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full Prescribing Information2
The storage and handling information in the Janssen COVID-19 Vaccine Fact Sheet supersedes the storage and handling information on the carton and vial labels.
Storage prior to First Puncture of the Vaccine Vial
Storage after First Puncture of the Vaccine Vial
Multiple microbiological challenge studies were performed to support the microbial safety of the Janssen COVID-19 Vaccine.8, 9
After the first dose has been withdrawn, hold the vial between 2°C to 8°C (36°F to 46°F) for up to 6 hours or at room temperature (maximally 25°C/77°F) for up to 2 hours. Discard the vial if vaccine is not used within these times.2 Maximum hold times for these 2 temperature ranges are not cumulative (i.e., The vaccine cannot be held at room temperature for 2 hours and then held refrigerated for another 6 hours).7, 8
If stored refrigerated after the first puncture, the vaccine can be moved to room temperature for brief periods of time for dose withdrawal. This does not impact the maximum 6-hour hold period in the refrigerator.7, 8
The Janssen COVID-19 Vaccine should not be exposed to direct sunlight or ultraviolet (UV) light.10
The Janssen COVID-19 vaccine can be exposed to indoor ambient light for 6 hours during preparation and administration.7
The primary vaccination regimen for the Janssen COVID-19 Vaccine is a single-dose (0.5 mL) administered to individuals 18 years of age and older.2
A single Janssen COVID-19 Vaccine booster dose (0.5 mL) may be administered at least 2 months after primary vaccination with the Janssen COVID-19 Vaccine, to individuals 18 years of age and older.2
A single booster dose of the Janssen COVID-19 Vaccine (0.5 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The eligible population(s) and dosing interval for the heterologous booster dose are the same as those authorized for a booster dose of the vaccine used for primary vaccination.
Visually inspect each dose in the dosing syringe prior to administration. The Janssen COVID-19 Vaccine is a colorless to slightly yellow, clear to very opalescent suspension. During the visual inspection,
Administer the Janssen COVID-19 Vaccine intramuscularly.
Observe recipients after vaccination for an immediate adverse reaction:
DOSE PREPARATION2 | |
---|---|
![]() | The Janssen COVID-19 Vaccine is a colorless to slightly yellow, clear to very opalescent suspension. Visually inspect the Janssen COVID-19 Vaccine vials for particulate matter and discoloration prior to administration. If either of these conditions exists, do not administer the vaccine. |
![]() | Before withdrawing each dose of vaccine, carefully mix the contents of the multi-dose vial by swirling gently in an upright position for 10 seconds. Do not shake.
|
![]() | Each dose is 0.5 mL. Each vial contains five doses.
|
![]() | The Janssen COVID-19 Vaccine does not contain a preservative.
|
ADMINISTRATION2 | |
![]() | Visually inspect each dose in the dosing syringe prior to administration. The Janssen COVID-19 Vaccine is a colorless to slightly yellow, clear to very opalescent suspension. During the visual inspection,
|
![]() | Administer the Janssen COVID-19 Vaccine intramuscularly. |
1 | United States Food and Drug Administration. Janssen COVID-19 Vaccine. FDA Emergency Use Authorization Letter. Available from: https://www.janssenlabels.com/emergency-use-authorization/Janssen+COVID-19+Vaccine-EUA.pdf. |
2 | Janssen COVID-19 Vaccine. Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full Prescribing Information. Janssen Biotech, Inc; https://www.janssenlabels.com/emergency-use-authorization/Janssen+COVID-19+Vaccine-HCP-fact-sheet.pdf. |
3 | Janssen Pharmaceutical Companies of Johnson & Johnson. Emergency use authorization (EUA) application for Ad26.COV2.S. Vaccines and Related Biological Products Advisory Committee. Meeting date: 26 February 2021. Presentation available from: https://www.fda.gov/media/146265/download. |
4 | Data on File. Janssen COVID-19 Vaccine Technical Document: TV-TEC-185069. Janssen Biotech, Inc.; 2020. |
5 | Data on File. Janssen COVID-19 Vaccine Technical Document: TV-TEC-177477. Janssen Biotech, Inc.; 2020. |
6 | Data on File. Janssen COVID-19 Vaccine. Vial Overfill. CMC Regulatory. 25 February 2021. |
7 | Data on File. Janssen COVID-19 Vaccine Technical Document: TV-TEC-183523. Janssen Biotech, Inc.; 2020. |
8 | Data on File. Janssen COVID-19 Vaccine Technical Document: TV-TEC-188332. Janssen Biotech, Inc.; 2020. |
9 | Data on File. Janssen COVID-19 Vaccine Technical Document: TV-TEC-183318. Janssen Biotech, Inc.; 2020. |
10 | Data on File. Janssen COVID-19 Vaccine Technical Document: TV-TEC-190932. Janssen Biotech, Inc.; 2020. |
11 | Data on File. Janssen COVID-19 Vaccine Technical Document: TV-TEC-181883. Janssen Biotech, Inc.; 2020. |